| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A commentary on the development of engineered phage as therapeutics
|
Barnard, Anne M.L.
|
|
|
26 |
9 |
p. 2095-2098
|
artikel
|
| 2 |
Adjunctive therapy for multidrug-resistant bacterial infections: Type III secretion system and efflux inhibitors
|
Moir, Donald T.
|
|
|
26 |
9 |
p. 2173-2181
|
artikel
|
| 3 |
Are outer-membrane targets the solution for MDR Gram-negative bacteria?
|
Walker, Scott S.
|
|
|
26 |
9 |
p. 2152-2158
|
artikel
|
| 4 |
A Special Issue on Antimicrobial Resistance
|
Jackson, Peter
|
|
|
26 |
9 |
p. 2079-2080
|
artikel
|
| 5 |
Challenges and opportunities in the discovery, development, and commercialization of pathogen-targeted antibiotics
|
Altarac, David
|
|
|
26 |
9 |
p. 2084-2089
|
artikel
|
| 6 |
Computational resources in the management of antibiotic resistance: Speeding up drug discovery
|
Maryam, Lubna
|
|
|
26 |
9 |
p. 2138-2151
|
artikel
|
| 7 |
Contents page 1
|
|
|
|
26 |
9 |
p. i
|
artikel
|
| 8 |
Contents page 2
|
|
|
|
26 |
9 |
p. ii
|
artikel
|
| 9 |
Fighting AMR with Host Immune Response Technology
|
Oved, Kfir
|
|
|
26 |
9 |
p. 2081-2083
|
artikel
|
| 10 |
Improving the ability of antimicrobial susceptibility tests to predict clinical outcome accurately: Adding metabolic evasion to the equation
|
Tasse, Jason
|
|
|
26 |
9 |
p. 2182-2189
|
artikel
|
| 11 |
Innovation in infectious disease therapies from immunology
|
O'Neil, Deborah A.
|
|
|
26 |
9 |
p. 2090-2094
|
artikel
|
| 12 |
Learnings from past failures: Future routes of antimicrobial drug discovery
|
Datta, Santanu
|
|
|
26 |
9 |
p. 2105-2107
|
artikel
|
| 13 |
Pseudomonas aeruginosa elastase (LasB) as a therapeutic target
|
Everett, Martin J
|
|
|
26 |
9 |
p. 2108-2123
|
artikel
|
| 14 |
Recent advances in Clp protease modulation to address virulence, resistance and persistence of MRSA infection
|
Ju, Yuan
|
|
|
26 |
9 |
p. 2190-2197
|
artikel
|
| 15 |
Recent development in the design of small ‘drug-like’ and nanoscale glycomimetics against Escherichia coli infections
|
Mousavifar, Leila
|
|
|
26 |
9 |
p. 2124-2137
|
artikel
|
| 16 |
Rifabutin for infusion (BV100) for the treatment of severe carbapenem-resistant Acinetobacter baumannii infections
|
Trebosc, Vincent
|
|
|
26 |
9 |
p. 2099-2104
|
artikel
|
| 17 |
Sortase A (SrtA) inhibitors as an alternative treatment for superbug infections
|
Alharthi, Sitah
|
|
|
26 |
9 |
p. 2164-2172
|
artikel
|
| 18 |
Spare and repair the gut microbiota from antibiotic-induced dysbiosis: state-of-the-art
|
Andremont, Antoine
|
|
|
26 |
9 |
p. 2159-2163
|
artikel
|
| 19 |
Targeted microbiome-sparing antibiotics
|
Avis, Tim
|
|
|
26 |
9 |
p. 2198-2203
|
artikel
|
Tijdschrift beschrijving